Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer

医学 伊立替康 吉西他滨 胰腺癌 内科学 肿瘤科 危险系数 胃肠病学 生物标志物 化疗 结直肠癌 癌症 生物 置信区间 生物化学
作者
Valeria Merz,Camilla Zecchetto,Raffaela Santoro,Francesca Simionato,Fabio Sabbadini,Domenico Mangiameli,Geny Piro,Alessandro Cavaliere,Michela Deiana,Maria Teresa Valenti,Diana Bazan,Vita Fedele,Sara Lonardi,Davide Melisi
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:26 (17): 4661-4669 被引量:22
标识
DOI:10.1158/1078-0432.ccr-20-0395
摘要

Abstract Purpose: Pancreatic cancer is one of the most lethal solid tumors, mainly because of its intrinsic chemoresistance. We identified TAK1 as a central hub sustaining this resistance. Nanoliposomal irinotecan (nal-IRI) is a novel treatment for metastatic gemcitabine-refractory pancreatic cancer. We endeavored to identify circulating markers for TAK1 activation predicting chemoresistance in this setting. Experimental Design: In vivo activity of nal-IRI was validated in an orthotopic nude murine model expressing TAK1-specific shRNA. Plasma concentration of 20 different cytokines were measured by a multiplex xMAP/Luminex technology in patients prospectively enrolled to receive nal-IRI plus 5-fluorouracil/leucovorin (5-FU/LV). The optimal cutoff thresholds able to significantly predict patients' outcome were obtained on the basis of the maximization of the Youden's statistics. Results: Differential expression profiling revealed the gene coding for IL8 as the most significantly downregulated in shTAK1 pancreatic cancer cell lines. Mice bearing shTAK1 tumors had significantly lower plasma levels of IL8 and experienced a significant reduction in tumor growth if treated with nal-IRI, whereas those bearing TAK1-proficient tumors were resistant to this agent. In a discovery cohort of 77 patients, IL8 was the circulating factor most significantly correlated with survival (plasma levels lower vs higher than cutoff: mPFS 3.4 months vs 2.8 months; hazard ratio [HR], 2.55; 95% CI, 1.39–4.67; P = 0.0017; median overall survival 8.9 months vs 5.3 months; HR, 3.51; 95% CI, 0.84–6.68; P = 4.9e−05). These results were confirmed in a validation cohort of 50 patients. Conclusions: Our study identified IL8 as the most significant circulating factor for TAK1 pathway activation and candidates IL8 as a potential predictive biomarker of resistance to nal-IRI in gemcitabine-refractory patients with pancreatic cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lm发布了新的文献求助10
刚刚
无所归兮应助曲艺采纳,获得10
1秒前
1秒前
yar应助alone采纳,获得30
2秒前
za==应助小赵采纳,获得10
2秒前
3秒前
豆芽发布了新的文献求助10
3秒前
oky发布了新的文献求助10
3秒前
wdy111应助迷路硬币采纳,获得20
5秒前
5秒前
6秒前
艺高人胆大鸡腿完成签到 ,获得积分10
9秒前
乐乐应助焦糖采纳,获得10
9秒前
科研通AI2S应助nalan采纳,获得10
10秒前
静_完成签到 ,获得积分10
10秒前
10秒前
雪白元蝶发布了新的文献求助10
11秒前
11秒前
11秒前
留白完成签到 ,获得积分10
12秒前
共享精神应助小圆采纳,获得10
12秒前
12秒前
慕青应助梵高的向日葵采纳,获得10
12秒前
SYLH应助科研通管家采纳,获得20
12秒前
czh应助科研通管家采纳,获得10
12秒前
12秒前
ding应助科研通管家采纳,获得10
12秒前
搜集达人应助科研通管家采纳,获得10
13秒前
打打应助科研通管家采纳,获得10
13秒前
13秒前
彭于彦祖应助科研通管家采纳,获得10
13秒前
彭于彦祖应助科研通管家采纳,获得30
13秒前
雯雯完成签到,获得积分10
13秒前
13秒前
13秒前
研友_VZG7GZ应助科研通管家采纳,获得10
13秒前
ED应助科研通管家采纳,获得10
13秒前
共享精神应助科研通管家采纳,获得10
13秒前
JamesPei应助科研通管家采纳,获得10
14秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Economic Geography and Public Policy 900
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021